Company Info
Phone(312) 416-8592
Year Established
2018
Ticker
MAIA
Exchange
NYSE
Contacts
Vlad Vitoc, MD, MBACEO
Jeffrey C. Himmelreich
Head of Finance
Sergei M. Gryaznov, PhD
CSO
Company Description
MAIA Biotechnology is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.